Replies to post #2334 on Enanta Pharmaceuticals Inc (ENTA)

[Rocky3]

So with expenses going up $50-75MM and revenue weak, it is possible for $175-200MM (or higher) loss in next 12 months. Sounds like they might need to raise more money sooner than later.

[DewDiligence]

Typo: FY3Q22—>FY4Q22.

[DewDiligence]

ENTA FY4Q22 CC transcript:

https://www.insidermonkey.com/blog/enanta-pharmaceuticals-inc-nasdaqenta-q4-2022-earnings-call-transcript-1100664/?singlepage=1

[DewDiligence]

ENTA FY1Q23* financials—12/31/22_pro_forma_cash=$270.1M† — a decrease of $37.1M relative to 9/30/22:

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-34

FY1Q23 royalty revenue was $22.6M, up from $20.3M in FY4Q22.

FY1Q23 R&D expenses were $40.9M, below the run rate for ENTA’s FY2023 guidance of $210-230M. FY1Q23 SG&A expenses were $12.7M, zzz inline with ENTA’s FY2023 guidance of $46-52M.

†Including a $28.7M tax refund due from IRS.

*ENTA’s fiscal years end on September 30.